Abstract: Embodiments of the invention are generally directed to a system and method of network loop detection and recovery. In one embodiment of the invention, a networked node contains a loop detection and recovery agent. The loop detection and recovery agent may include a loop detection module and a loop recovery module. The loop detection module may be independent of a redundancy protocol implemented by the networked node. In contrast, the loop recovery module may be embedded in the redundancy protocol implemented by the networked node.

Abstract: The present invention relates to compounds of formula (1), its solvates and pharmaceutically acceptable salts having antifungal activity and its pharmaceutical composition comprising an effective amount of compound of formula (1) wherein R is substituted alkyl, alkenyl, aryl, heteroaryl, 2-thienyl, 3-thienyl, halothienyl, haloalkyl, halophenyl, or pyrrolyl; and R1 and R2, each independent of the other, are hydrogen, halogen, or alkoxy. The invention also relates to a process for the preparation of said compounds by contacting the intermediate alcohol, prepared from 1,2-O-isopropylideneglyceraldehyde and substituted phenylacetates, with acid chlorides under appropriate conditions to obtain some of the preferred compounds of the invention.

Abstract: The present invention provides in-place, phased migration from one version of a database software application release version to another of a software release version. A method for phased migration of a database software application comprises developing a database software application in a plurality of phases of development, at least some of the plurality of phases of development requiring a change in a schema of a database used by the database software application; and for each of the phases of development that requires a change in a schema of the database, performing phase-wise migration of the database by sequentially modifying the schema of the database based on the changes in the schema of the database required by each phase.

Abstract: The Present invention relates to a process for the preparation of (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine of formula 1. (RS) 3-Methyl-1-(2-piperidinyl phenyl butyl amine having formula 1 is an important key intermediate for the synthesis of repaglinide of formula 2 an oral hypoglycemic agent.

Abstract: A process for preparing racemic mixtures containing nearly equal amounts of stereo isomers of compounds of formula (I), or their salts, by heating an enantiomerically enriched material with thionyl chloride. A required useful enantiomer may thereby be recovered from unwanted mother liquors that would otherwise be otherwise be discarded.

Abstract: The Present invention relates to a process for the preparation of (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine of formula 1.

Abstract: A process for preparing racemic mixtures containing nearly equal amounts of stereo isomers of compounds of formula (I), or their salts, by heating an enantiomerically enriched material with thionyl chloride.